Pharmaceuticals · NYSE

JNJJohnson & Johnson

Last close
$285.75 +0.8%
52-week range
$193.55 to $288.11
Market cap
$688B
Next earnings
Not scheduled

Fiscal 2025 at a glance

Revenue
$94.2B
+6% vs FY24
Net income
$26.8B
+91% vs FY24
Free cash flow
$19.7B
-1% vs FY24
Net cash
-$29.8B
Cash $20.1B, debt $49.9B

Stock price

+155% since Dec 2016

Valuation vs its own 10 years

Above its 10-year median on all 4 multiples

Where each multiple sits today inside its own range since 2017, measured at every quarter end. The thin tick is the median.

P/E, trailing
43.4x
9.6x358x
90th percentile, above its median of 24.1x
Price / sales
6.9x
4.0x6.9x
Highest point in its range, above its median of 4.7x
EV / EBITDA
26.7x
11.2x26.7x
Highest point in its range, above its median of 16.0x
Price / free cash flow
33.4x
16.6x33.4x
Highest point in its range, above its median of 20.7x

Key statistics

Trailing 12 months unless noted, through the quarter ending 2026-09-27. Every figure carries its unit.

Valuation

P/E
43.4x
Earnings yield
2.3%
Price / sales
6.9x
Price / book
8.4x
Price / operating cash flow
26.3x
EV / EBITDA
26.7x
EV / sales
7.2x
Free cash flow yield
3.0%

Profitability

Gross margin
67.6%
Operating margin
n/a
Net margin
16.2%
Return on equity
19.7%
Return on capital
n/a

n/a: Not reported

Growth per year

Revenue, 3 years
+5.6%
Revenue, 5 years
+2.7%
Revenue, 9 years
+3.0%
EPS, 3 years
+17.9%

Balance sheet

Cash and investments
$17.2B
Total debt
$44.7B
Net cash
-$27.4B
Debt / equity
0.55x
Current ratio
1.02x

Shares and dividend

Shares outstanding
2.41B
Share count, 5 years
-9.0%
Beta, 1 year
-0.08
Dividend yield
1.8%
Dividend per share, TTM
$5.28
Payout ratio
n/aNot meaningful

Ten years of the business

Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.

Revenue and net incomeLatest quarter $25.4B
RevenueNet income
Gross profitLatest quarter $17.3B
EBITDALatest quarter $2.37B
Margins68 / 1%
GrossOperatingNet
Earnings per shareLatest quarter $0.09
Cash flowLatest quarter $7.72B
OperatingCapexFree
Cash vs debtLatest quarter $17.2B
Cash and investmentsTotal debt
P/E historyNow 43.4x
P/E, median 24.1x dashed
P/S historyNow 6.9x
P/S, median 4.7x dashed

Where the revenue comes from

Med Tech went from 34% to 36% of revenue in 3 years

Share of revenue by business segment, fiscal 2022 to 2025, as reported in the 10-K.

Innovative MedicineMed Tech
FY22
66%34%
$80.0B
FY23
64%36%
$85.2B
FY24
64%36%
$88.8B
FY25
64%36%
$94.2B
Fiscal 2025 by business segment
Business segmentRevenueSharevs FY24
Innovative Medicine$60.4B64.1%+6%
Med Tech$33.8B35.9%+6%

Pharmaceuticals peers

The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.

CompanyMarket capRevenue growth Operating marginP/EP/SP/E vs own history
LLY ELI LILLY & Co $1.36T +46% n/a46.8x15.7x 60th percentile
JNJ Johnson & Johnson $688B +8% n/a43.4x6.9x 90th percentile
MRK Merck & Co., Inc. $364B +5% n/a152x5.4x 98th percentile
PFE Pfizer Inc $165B +1% n/a41.2x2.6x 97th percentile
BMY Bristol Myers Squibb Co $130B +4% n/a14.1x2.6x 13th percentile
TEVA Teva Pharmaceutical Industries Ltd $51.9B -16% 10.2%103x3.7x Not enough history

The company

Sector
Health Care
Industry
Pharmaceuticals
CEO
Joaquin Duato
Employees
138,200 (as of 2026)
Founded
1886
Headquarters
New Brunswick, NJ
Fiscal year ends
Late December
Website
jnj.com

What it does

Johnson & Johnson is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey. The company is ranked No. 42 on the 2026 Fortune 500 list of the largest United States corporations. In 2026, the company was ranked 43rd in the Forbes Global 2000.

Description from Wikipedia (CC BY-SA).

Around the numbers

What the rest of EdgeStacker knows about JNJ.

Next report

No confirmed report date in the next 95 days yet.

Open the Earnings Hub
Big funds, latest 13F

Held by 4,368 active funds. Crowd level: quiet.

Open the Smart money tab